Compare Macy's Inc (M) vs TG Therapeutics Inc (TGTX) Price & Performance

Macy's (M) trades at $22.67, down 0.53% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The stock shows attractive valuation with a P/E of 8.35 and P/S of 0.27, supported by a 15.99% ROE. Recent earnings have consistently beaten estimates, and the company's 'A Bold New Chapter' strategy is driving digital and omnichannel growth, though revenue has declined from 2022 peaks. Cash flow trends are improving, with net cash flow turning positive in 2024 and 2025.

The outlook is cautiously optimistic, with a consensus price target of $24.25 offering potential upside. Investment opportunities include deep value, dividend yield, and successful turnaround execution. Key risks are competitive pressures, uneven sales growth, and macroeconomic sensitivity affecting consumer spending. Analyst sentiment is mixed, with 32% buy ratings but 51% hold, reflecting uncertainty around sustained momentum.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.